• Antonio L Bartorelli, Patrick W Serruys, Karine Miquel-Hébert, Shui Yu, Wes Pierson, Gregg W Stone, and SPIRIT II SPIRIT III Investigators.
• Centro Cardiologico Monzino, Istituto di Ricovero e Cura a Carattere Scientifico and Department of Cardiovascular Sciences, University of Milan, Monzino Via Parea 4, Milan, Italy. antonio.bartorelli@ccfm.it
• Catheter Cardiovasc Interv. 2010 Jul 1; 76 (1): 60-6.

ObjectivesTo evaluate the safety and efficacy of the XIENCE V everolimus-eluting stent compared to the TAXUS paclitaxel-eluting stent in small vessels.BackgroundThe XIENCE V everolimus-eluting stent (EES) has been shown to improve angiographic and clinical outcomes after percutaneous myocardial revascularization, but its performance in small coronary arteries has not been investigated.MethodsIn this pooled analysis, we studied a cohort of 541 patients with small coronary vessels (reference diameter <2.765 mm) by using patient and lesion level data from the SPIRIT II and SPIRIT III studies. TAXUS Express (73% of lesions) and TAXUS Liberté (27% of lesions) paclitaxel-eluting stents (PES) were used as controls in SPIRIT II. In SPIRIT III, Taxus Express(2) PES was the control.ResultsMean angiographic in-stent and in-segment late loss was significantly less in the EES group compared with the PES group, (0.15 +/- 0.37 mm vs. 0.30 +/- 0.44 mm; P = 0.011 for in-stent; 0.10 +/- 0.38 mm vs. 0.21 +/- 0.34 mm; P = 0.034 for in-segment). EES also resulted in a significant reduction in composite major adverse cardiac events at 1 year (19/366 [5.2%] vs. 17/159 [10.7%]; P = 0.037), due to fewer non-Q-wave myocardial infarctions and target lesion revascularizations. At 1 year, the rate of non-Q-wave myocardial infarction was significantly lower in the EES group compared with that of the PES group (6/366 [1.6%] vs. 8/159 [5.0%]; P = 0.037).ConclusionsIn patients with small vessel coronary arteries, the XIENCE V EES was superior to the TAXUS PES.(c) 2010 Wiley-Liss, Inc.

40 keywords...

hide…